Evaluating only Biomea Fusion’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Market timing.
Key Events Timeline
FOUNDING
MILESTONE
CRISIS
SHUTDOWN
Full Analysis
Free · no account needed
Documented cause
Biomea Fusion developed covalent small molecule therapies for cancer, raising $190M. The lead drug BMF-219 showed promise in preclinical models but failed to demonstrate adequate tolerability in clinical trials. The company wound down in May 2024 within weeks of the disappointing data readout.
Lesson
“Tolerance profiles in oncology must be de-risked in earlier studies before raising institutional capital at scale.”